Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality

and Alicia Young and Ross L. Prentice, Fred Hutchinson Cancer Research Center, Seattle, WA.
Journal of Clinical Oncology (Impact Factor: 18.43). 09/2012; 30(32). DOI: 10.1200/JCO.2012.42.7732
Source: PubMed

ABSTRACT PURPOSEDuring the intervention phase in the Women's Health Initiative (WHI) clinical trial, use of estrogen plus progestin reduced the colorectal cancer diagnosis rate, but the cancers were found at a substantially higher stage. To assess the clinical relevance of the findings, analyses of the influence of combined hormone therapy on colorectal cancer incidence and colorectal cancer mortality were conducted after extended follow-up. PATIENTS AND METHODS
The WHI study was a randomized, double-blind, placebo-controlled clinical trial involving 16,608 postmenopausal women with an intact uterus who were randomly assigned to daily 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate (n = 8,506) or matching placebo (n = 8,102). Colorectal cancer diagnosis rates and colorectal cancer mortality were assessed.ResultsAfter a mean of 5.6 years (standard deviation [SD], 1.03 years) of intervention and 11.6 years (SD, 3.1 years) of total follow-up, fewer colorectal cancers were diagnosed in the combined hormone therapy group compared with the placebo group (diagnoses/year, 0.12% v 0.16%; hazard ratio [HR], 0.72; 95% CI, 0.56 to 0.94; P = .014). Bowel screening examinations were comparable between groups throughout. Cancers in the combined hormone therapy group more commonly had positive lymph nodes (50.5% v 28.6%; P < .001) and were at higher stage (regional or distant, 68.8% v 51.4%; P = .003). Although not statistically significant, there was a higher number of colorectal cancer deaths in the combined hormone therapy group (37 v 27 deaths; 0.04% v 0.03%; HR, 1.29; 95% CI, 0.78 to 2.11; P = .320). CONCLUSION
The findings, suggestive of diagnostic delay, do not support a clinically meaningful benefit for combined hormone therapy on colorectal cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Postmenopausal hormone therapy (PMHT) is used for the relief of menopausal symptoms, but the dosage has varied greatly throughout its existence. By the end of the 1990s, PMHT was mainly used to prevent chronic diseases such as osteoporosis, coronary heart disease and dementia, and large prevention trials were undertaken in this context. Following the initial negative reports of these trials, use of PMHT dramatically decreased. These reports noted surprisingly increased risks, notably of coronary heart disease, stroke and breast cancer, in people who used PMHT. Nowadays, considering the currently available data, it seems that an important distinction should be made between the treatment of climacteric symptoms in young, generally healthy, postmenopausal women and the prevention of chronic diseases in elderly women. PMHT seems to be beneficial and safe for postmenopausal symptomatic women aged <60 years. Treatments with a high safety profile should be the preferred option, including low-dose PMHT, oestrogen-only therapy in women who have had a hysterectomy, and vaginal oestrogen therapy for women with atrophic vaginitis. Nonandrogenic progestin might have a reduced thrombotic and breast cancer risk, and transdermal oestrogen could have a reduced thrombotic risk. Nevertheless, PMHT should not be used for the prevention of chronic diseases in the elderly (>70 years old) owing to the increased risk of stroke and breast cancer in these patients.
    Nature Reviews Endocrinology 02/2013; 9(4). DOI:10.1038/nrendo.2013.17 · 12.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An estimated 140,000 new cases of colorectal cancer (CRC) were diagnosed in the USA in 2013. This review focuses on primary, secondary, and tertiary efforts to improve outcomes for patients at risk of CRC. Primary prevention to prevent the occurrence of CRC should focus on the reduction of modifiable CRC risk factors, including education regarding the deleterious effects of Western diets consisting of red and processed meats and the dangers of a sedentary lifestyle and obesity. Foods containing folates, vitamin D, and calcium may be protective against CRC and their consumption should likely be encouraged. Secondary preventive screening efforts can have a profound effect on reducing mortality by identifying neoplasia when precancerous lesions such as adenomas may be removed or when early-stage CRCs exist. Efforts must be made to increase the uptake of CRC screening on a worldwide level. The most resounding data for pharmacologic success in the prophylaxis of colorectal neoplasia belong to the class of aspirin and nonsteroidal anti-inflammatory drugs. Future therapies improving the efficiency of CRC screening modalities and genomic medical breakthroughs to personalize prophylactic treatments will change the way CRC prevention is viewed.
    Current Colorectal Cancer Reports 03/2013; DOI:10.1007/s11888-013-0201-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Celebrating its tenth anniversary, the Gastrointestinal Cancers Symposium is a world class, international conference focused on research and multidisciplinary management of digestive tract malignancies, co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, the American Gastroenterological Association Institute and the Society of Surgical Oncology. This premium meeting was held from 24 to 26 January 2013 in San Francisco (CA, USA) and, in line with its principal mission, it sought to globally embrace prevention, screening, diagnostics, translational research and multimodal treatment, moving on three major anatomic tracks (upper gastrointestinal cancers, pancreatic/hepatobiliary tumors and colorectal malignancies). Over 2000 healthcare professionals gathered at this valuable 3day scientific event, which included plenary educational sessions and oral presentations of the top-rated abstracts, as well as the exposition of nearly 600 posters. This short article offers a summarized opinion-based overview of the most significant studies presented at the meeting that are likely to impact on clinical practice as well as new drug development, as best exemplified by the three most important messages of the whole meeting: the value of nanoparticle albumin-bound paclitaxel in metastatic pancreatic cancer; that of ramucirumab in second-line gastric cancer; and that of capecitabine and bevacizumab in elderly advanced colorectal cancer patients.
    Future Oncology 05/2013; 9(5):645-8. DOI:10.2217/fon.13.34 · 2.61 Impact Factor
Show more